Roche Holding AG (RHHBY)

Market Cap	346.31B +30.5%
Revenue (ttm)	77.92B -0.8%
Net Income	15.27B +30.9%
EPS	18.98 +30.6%
Shares Out	n/a
PE Ratio	22.67
Forward PE	16.85
Dividend	0.97 (1.80%)
Ex-Dividend Date	Mar 13, 2026

Volume	1,091,171
Open	54.63
Previous Close	54.63
Day's Range	54.00 - 54.66
52-Week Range	39.50 - 60.85
Beta	0.35
Analysts	Buy
Price Target	60.59 (+11.89%)
Earnings Date	Oct 22, 2026

About Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavir...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1896
• Employees: 103,249
• Stock Exchange: OTCMKTS
• Ticker Symbol: RHHBY

Financial Performance

In 2025, Roche Holding AG's revenue was 63.36 billion, an increase of 1.54% compared to the previous year's 62.40 billion. Earnings were 12.88 billion, an increase of 55.61%.

Financial numbers in CHF

Analyst Summary

According to 8 analysts, the average rating for RHHBY stock is "Buy." The 12-month stock price target is $60.59, which is an increase of 11.89% from the latest price.

Price Target

$60.59

(11.89% upside)

Analyst Consensus: Buy

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Sep 19, 2026

Data Sources Report a data error